CHA Vaccine Research Institute (KOSDAQ: 261780)

Market Cap	82.07B
Revenue (ttm)	370.66M
Net Income (ttm)	-4.26B
Shares Out	26.73M
EPS (ttm)	-159.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	69,932
Average Volume	110,108
Open	3,090.00
Previous Close	3,115.00
Day's Range	3,050.00 - 3,155.00
52-Week Range	2,840.00 - 6,100.00
Beta	0.71
RSI	41.36
Earnings Date	n/a

About CHA Vaccine Research Institute

Cha Vaccine Research Institute Co., Ltd., a research-oriented biotechnology company, researches and develops a range of vaccine products targeting infectious and chronic diseases. Its product pipeline includes HBV vaccine that is in Phase IIb planning for the prevention of hepatitis B; Adjuvanted HBV vaccine that is in Phase I/IIa for the treatment of chronic hepatitis B; and VZV Vaccine, which is in pre-clinical planning stage for the prevention of Herpes Zoster. The company also develops influenza vaccine, recombinant MBL, TB vaccine, and can...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 261780

Financial Performance

In 2023, CHA Vaccine Research Institute's revenue was 294.12 million, an increase of 63.87% compared to the previous year's 179.48 million. Losses were -1.75 billion, -73.95% less than in 2022.